IPROOV/EUROSTAR
iProov , the world leader in biometric face authentication technology, and Eurostar , the high-speed passenger rail service linking the UK with mainland Europe, have announced that their trial of a contactless fast-track service, SmartCheck, is now live.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211205005029/en/
SmartCheck enables passengers to complete secure ticket verification and UK exit check on their mobile devices prior to travel. As part of the trial, Business Premier and Carte Blanche ticket holders will be able to scan their identity documentation using their iPhones before arriving at the station, completing a brief biometric face scan to verify that they are the genuine holder of the identity document. The biometric face verification, which uses iProov’s Genuine Presence Assurance technology, is then linked to their e-ticket, with confirmation sent to the passenger.
On arrival at St Pancras International station, passengers proceed through a dedicated SmartCheck lane. A brief face scan at the ticket gate verifies that the customer has completed the ticket check, with no sharing of paper or electronic tickets needed. A second face scan at the UK Exit Check allows Eurostar to verify that the passenger has completed their passport information, again replacing the need for travelers to hand over documentation.
SmartCheck aims to revolutionize the travel experience by making it completely effortless for the passenger, while maximizing privacy and increasing reassurance through improved security. The aim is to eliminate queues and expedite the boarding process to further improve customer satisfaction, especially for frequent travelers.
The concept is being brought to train travel as part of the First of a Kind 2020 competition run by Innovate UK, funded by the Department for Transport (DfT). The initiative supports research, development and innovation in the UK rail industry. At this time, the trial involves a limited number of invited passengers and is focused on the check-in and exit control processes operated by Eurostar at St Pancras Station and not the UK or Schengen Entry controls.
“This secure, convenient and privacy-protecting technology will make life easier and safer for travelers around the world,” said Andrew Bud, Founder and CEO, iProov. “The days of rooting around in your bag for your passport or hoping that your phone battery doesn’t run out before you show your e-ticket at the gate are over. It’s effortless and convenient while also delivering the reassurance and security that travelers expect.”
“We are committed to working closely with governments to introduce new tools and technology that streamline the check in and border process,” said Gareth Williams, Strategy Director and Company Secretary, Eurostar. “Face biometric technology, which we start trialling today, is a fast and contactless solution which will enable secure passenger checks to take place more efficiently and provide a seamless start to the Eurostar customer journey.”
“Our investment into the First of a Kind competition, supporting ingenious inventions on our rail network, is driving real-world innovations as we build the railway of tomorrow,” said Grant Shapps, Transport Secretary. “The brand new contactless travel technology from iProov and Eurostar is a window into the future of border control, of smoother, more seamless and convenient journeys.”
iProov’s Genuine Presence Assurance technology enables organizations to securely verify the identity of consenting online individuals in a way that is completely effortless for the user. A brief, multi-dimensional biometric face scan combines light, time and space to verify that a remote user is the right person, a real person, and that they are authenticating in real time. This highly secure process, supported by iProov’s active threat management system, protects against spoof attacks and can be used on any smartphone, tablet or computer with a user-facing camera.
The trial was developed in close partnership with Eurostar and WorldReach Software, now part of global identity and data security company, Entrust . All personal data is processed in compliance with GDPR law, with full passenger consent. It is not shared with any party outside the trial and is deleted within six hours of the user travelling.
iProov technology is in use throughout the world, with customers including the US Department of Homeland Security, the UK Home Office, the NHS, the Australian Taxation Office, the Singapore Government and many banks and enterprises.
About iProov
Launched in 2013, iProov is the world leader in online facial biometric authentication, working with governments, banks and other enterprises to securely verify customer identity. Used for effortless onboarding and authentication, customers include the U.S. Department of Homeland Security, the UK Home Office, the UK National Health Service (NHS), the Australian Taxation Office, GovTech Singapore, Rabobank, ING, and others. iProov’s technologies include Liveness Assurance and Genuine Presence Assurance, which ensures that an online customer is the right person, a real person, and is authenticating right now. This protects against spoof attacks from photos, videos, masks and digital injection attacks and the emerging threat of deepfakes. iProov was recognized as a Gartner Cool Vendor 2020 in Identity Access Management & Fraud Detection. For more information, please see www.iproov.com or follow us on LinkedIn or Twitter .
About Eurostar
For more information, please contact press.office@eurostar.com
Eurostar is the high-speed passenger service linking London St. Pancras International with city centre stations in mainland Europe, via the Channel Tunnel. Eurostar was established in 1994 as a partnership between three railway companies: SNCF, SNCB and LCR (London and Continental Railways). On 1 September 2010, Eurostar became a single, unified corporate entity owned by three shareholders: SNCF, SNCB and LCR. LCR’s holding was transferred to the Treasury in 2014 and sold by the UK government to a consortium comprising Caisse de Depot et Placement du Quebec (CDPQ) and Hermes Infrastructure in May 2015.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211205005029/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Clears First Extended Depth of Focus Contact Lens for Presbyopia23.12.2025 18:07:00 CET | Press release
Deseyne® (vifilcon C) Daily Disposable Soft (Hydrophilic) Contact Lens for Presbyopia with Extended Depth of Focus (EDOF) Delivers Continuous Vision at All Distances—Redefining Presbyopia Correction The Cataltheia Group and its U.S. subsidiary, Bruno Vision Care LLC, a leader in eye health innovation, today announced that the U.S. Food and Drug Administration (FDA) has cleared the first and only Daily Disposable Soft (Hydrophilic) Contact Lens for Presbyopia utilizing patented Extended Depth of Focus (EDOF) optical design technology, enabling commercial distribution in the United States. Deseyne® delivers smooth, continuous focus across near, intermediate, and distance vision, providing clear, natural vision without compromise. This performance is enabled by Cataltheia’s patented hyper-refractive central zone, engineered to precisely redirect light in a controlled manner. The result is a clear clinical advantage over the only other available contact lens option for presbyopia, multifoc
Aramco Awards SLB Long-Term Contract to Support Kingdom’s Unconventional Gas Production Growth23.12.2025 14:58:00 CET | Press release
Five-year contract to drive innovation in stimulation, intervention, digital and frac automationAgreement underscores gas as a pivotal fuel for global energy demand and a bridge to lower-carbon systems Global technology company SLB (NYSE: SLB) has been awarded a five-year contract by Aramco to provide stimulation services for its unconventional gas fields. This award is part of a broader multi-billion contract, supporting one of the largest unconventional gas development programs globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251223074948/en/ The contract encompasses advanced stimulation, well intervention, frac automation, and digital solutions, which are important to unlocking the potential of Saudi Arabia’s unconventional gas resources. The contract encompasses advanced stimulation, well intervention, frac automation, and digital solutions, which are important to unlocking the potential of Saudi Arabia’s unconve
Tabelog, Japan's Largest (*1)Restaurant Search and Reservation Service,Launches Multilingual App for International Visitors23.12.2025 14:00:00 CET | Press release
Experience Japan's Authentic Culinary Scene in Your Language — From Search to Reservation, All on Your SmartphoneRanked No. 1 in Downloads Among "Japanese Gourmet Search Apps" Chosen by International Travelers (*2) Tabelog (https://tabelog.com/en/), Japan's largest restaurant search and reservation service operated by Kakaku.com, Inc., launched its multilingual smartphone application (iOS/Android) for international travelers on Monday, November 17, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251221963753/en/ The Tabelog Multilingual App for International Travelers — Japan's Largest Restaurant Search and Reservation Service With approximately 100 million monthly users(*3), Tabelog is Japan's premier service widely used by Japanese locals for daily restaurant discovery. Its database is unrivaled domestically, featuring information on approximately 890,000 establishments nationwide and over 85 million reviews and photo
BeOne Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference23.12.2025 12:01:00 CET | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, with a presentation at 7:30 am PST. Live webcasts of these events can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com, https://hkexir.beonemedicines.com, https://sseir.beonemedicines.com. Archived replays will be available on the Company’s website. About BeOne Medicines BeOne Medicines is a global oncology company based in Switzerland that is discovering and developing innovative treatments that are more accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. With a growing global team of nearly 12,000 colleagues spanning six continents, the Company is committed to
I-care Becomes a Unicorn23.12.2025 10:45:00 CET | Press release
The Belgian company has surpassed the billion-euro valuation mark following a €20 million fundraising and refinancing round. I-care announces the completion of a €20 million fundraising and refinancing operation, carried out as a round reserved for existing shareholders and employees. Based on this operation, the group's valuation reaches €1 billion, making I-care a unicorn. "Becoming a unicorn is a symbolic milestone. To achieve this, we chose to invest before reaping the rewards: we bet on AI when few believed in it, we prioritized R&D, and we built our own production unit. These choices were sometimes difficult, but they were essential to staying ahead of the game. Today, our results confirm that this strategy was the right one," explains Fabrice Brion, CEO of I-care. This fundraising round is the first step in a three-phase development plan. Following the “Eau Rouge” operation in 2022, which enabled I-care to become the world leader in predictive maintenance, the company has now se
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
